Pages

Showing posts with label about. Show all posts
Showing posts with label about. Show all posts

Thursday, July 9, 2009

The RNAi Therapeutics Blog is Back

After taking a break for almost a year to finish up my post-doctoral studies and to figure out what to do with my future, I have decided to pick up writing this blog again. In addition to what I hope will be a small contribution to explaining RNAi Therapeutics to the scientifically and financially interested public, it will also help me to better feel the pulse of RNAi Therapeutics through my interactions with you. So please feel free to comment. Initially, I will only comment when there is highly significant breaking news and will become more active again starting mid-September. There should be much to write about with first clinical data from the Alnylam and Tekmira SNALP-siRNA trials coming up which in my opinion could be a real game changer. Fingers crossed!
Posted by at 11 comments:
Labels:
Subscribe to: Posts (Atom)
By Dirk Haussecker. All rights reserved.

Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.